HMOX1 and neuroblastoma: A study conducted by Furfaro et al. reported that NRF2 and HO-1 upregulation decrease the efficacy of bortezomib (BTZ)—the first selective and reversible 26S PI tested in clinical trials [60]—in treating NB cells.